Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo.

AUTOR(ES)

Udvardy, A

RESUMO

In the studies reported here we have used topoisomerase II as a model system for analyzing the factors that determine the sites of action for DNA-binding proteins in vivo. To localize topoisomerase II sites in vivo we used an inhibitor of the purified enzyme, the antitumor drug VM-26. This drug stabilizes an intermediate in the catalytic cycle, the cleavable complex, and substantially stimulates DNA cleavage by topoisomerase II. We show that lysis of VM-26 treated tissue culture cells with sodium dodecyl sulfate induces highly specific double-strand breaks in genomic DNA, and we present evidence indicating that these double-strand breaks are generated by topoisomerase II. Using indirect end labeling to map the cleavage products, we have examined the in vivo sites of action of topoisomerase II in the 87A7 heat shock locus, the histone repeat, and a tRNA gene cluster at 90BC. Our analysis reveals that chromatin structure, not sequence specificity, is the primary determinant in topoisomerase II site selection in vivo. We suggest that chromatin organization may provide a general mechanism for generating specificity in a wide range of DNA-protein interactions in vivo.

Documentos Relacionados

• In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin.
• Differential DNA sequence recognition is a determinant of specificity in homeotic gene action.
• Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin.
• RNA structure, not sequence, determines the 5' splice-site specificity of a group I intron.
• A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo.